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BIOMARKERS OF MILD COGNITIVE
IMPAIRMENT AND ALZHEIMER’S DISEASE

logic markers of AD, it is unclear if they are involved in the
etiology ofAD or are merely end products of neurodegenera

FIELD OF THE INVENTION

may begin 20 to 30 years before the onset of clinical symp

tion. Additionally, it has been suggested that AD pathology
toms (Davies et al. Neurology 3811688-93 (1988); Price and
Morris Ann Neurol 451358-68 (1999)). During the preclinical
period, NET and SP increase until reaching a critical thresh
old When clinical symptoms appear.

The present invention relates to the ?eld of detection and of

monitoring treatment of neurodegenerative disorders, includ
ing Alzheimer’s disease and mild cognitive impairment
(MCI). More particularly, the present invention relates to

Without a clear genetic in?uence on sporadic AD several

etiologic/pathogenic hypotheses have been suggested includ
ing energy metabolism defects, de?ciencies of neurotrophic
factors, glutamate toxicity, mitochondrial defects, trace ele

proteinaceous biomarkers that can be measured in biological
?uids, Which can be used to aid in the detection of neurode

generative disorders, including Alzheimer’ s disease and mild

cognitive impairment.
BACKGROUND OF THE INVENTION

ment toxicity and free radical mediated toxicity.
Clinically, AD is characterized by a loss of spontaneity,
drive and initiative, a progressive Worsening of memory,
behavioral changes, onset betWeen 40 and 90, and the absence

Alzheimer’s disease (AD), an age-associated dementing
disorder, currently affects 4 million Americans and is the
fourth leading cause of death in the US. The prevalence ofAD

of systemic disorders or other brain diseases. The main clini
cal feature of AD is a progressive cognitive decline leading to

doubles every 5.1 years from 1% of Americans ages 65-69 to

memory loss. The memory dysfunction involves impairment
20

~39% of Americans age 90-95 (Jorm et al. Acta Psychiat

short-term memory loss. In the early (mild) and moderate
stages of the illness, recall of remote Well-leamed material

Scand 761465-79 (1987). With aging of the “baby boom”
generation, the largest segment of the US population, there

may appear to be preserved, but neW information cannot be

may be 14 million Americans With AD by 2040 unless pre
ventative strategies are developed. With a mean survival time
of 8.1 years and a range of 1 to 25 years AD is a groWing
socio-economic and medical problem With an estimated cost
of 100 billion dollars per year in the US alone.

25

30

cases account for less than 5% of all AD subjects. Currently,

tion. Impairments of judgment and problem solving are fre
35

The tWo hallmark pathologic markers of AD examined at
autopsy are NET and SP. NFT are intracellular deposits of

quently seen.
Non-cognitive or behavioral symptoms are also common

Pathologically, the AD brain is characterized by a loss of
total brain Weight, neuron loss and shrinkage, synapse loss,

neuropil thread formation, abundance of neuro?brillary
tangles (NFT) and senile plaques (SP) and by a proliferation
of reactive microglia and astrocytes in particular brain
regions including the hippocampus, amygdala and nucleus
basalis of Meynert (nbM).

phrases and cliches. Di?iculty in naming everyday objects is
often prominent. Complex de?cits in visual function are
present in many AD patients, as are other focal cognitive
de?cits such as apraxia, acalculia and left-right disorienta

protein (APP) are associated With familial AD (FAD) these
there are no knoWn genetic mutations associated With spo
radic AD.

adequately incorporated into memory. Disorientation to time
is closely related to memory disturbance.
Language impairments are also a prominent part of AD.
These are often manifest ?rst as Word ?nding dif?culty in

spontaneous speech. The language of the AD patient is often
vague, lacking in speci?cs and may have increased automatic

Risk factors associated With AD include aging, presence of

APOE-4 alleles, family history, head injury, loW educational
attainment and loW linguistic ability early in life. Although
mutations in presenilin 1 and 2 and the amyloid precursor

of learning neW information Which is often characterized as

in AD and may account for an even larger proportion of

caregiver burden or stress than the cognitive dysfunction.
40

Personality changes are commonly reported and range from
progressive passivity to marked agitation. Patients may
exhibit changes such as decreased expressions of affection.
Depressive symptoms are present in up to 40% of AD sub

jects. A similar rate for anxiety has also been reported. Psy
chosis occurs in 25% of AD subjects. In some cases, person
45

hyperphosphorylated tau, a microtubule associated protein in

ality changes may predate cognitive abnormality.
Currently, clinical diagnosis of AD is based on structured

neuronal axons. The normal function of tau is to bind tubulin

intervieWs (patient histories), and neurop sychological exami

in axonal microtubules and promote stabilization (Goedert et
al. EMBO J 81393-99 (1989), Buee et al. Brain Res Brain Res
Rev 33195-130 (2000)). As such, tau is essential for axonal

nations coupled With imaging or neurophysiological scans
(CT, MRI, PET and/or SPECT scans and EEG) to rule out
50

other explanations of memory loss including temporary (de

function and transport. Tau has 30 potential phosphorylation
sites (Iqbal et al. J Neural Transm Suppl 621309-319 (2002);

pression or vitamin B12 de?ciency) or permanent conditions
(stroke) and is based on NINCDS-ADRDA Work group cri

Buee et al. Brain Res Brain Res Rev 33195-130 (2000) and
abnormal phosphorylation is observed in AD NFT leading to
a loss of ability to bind microtubules (Iqbal et al. J Neurol

teria (McKhann et al. Neurology 341939-48 (1984) and the
American Psychiatric Association Diagnostic and Statistical
Manual of Mental Disorders (4th Ed. Washington DC, Am

55

591213-222 (2000).

Psychiatric Assoc. (1997).

Senile plaques are extracellular deposits composed of a
central core of amyloid [3 peptide (A6), a 40 or 42 amino acid

Unfortunately, clinical diagnostic methods are not fool
proof. Evidence based revieW of current literature shoWs
clinical diagnostic accuracy of 65 to 90%. Higher accuracy
rates are generally associated With specialized centers
(memory disorder clinics) focused on memory disorders
Whereas loWer rates are likely associated With primary care

polypeptide derived from the amyloid precursor protein
(APP). Surrounding the amyloid core are dystrophic neurites
and reactive glia. Formation of AB occurs through combined
action of beta and gamma secretase cleavage of APP leading
to the neurotoxic A[340/42. Mutations inAPP associated With
FAD are associated With increased generation of A[340/42.
Mutations in presenilin-1 and 2 (gamma secretases) are also
associated With FAD and lead to increased production of
A[340/42 . Although NET and SP are the hallmark neuropatho

60

physicians. Additionally, accuracy of the clinical diagnosis is
likely loWer during early stages of the disease When symp
65

toms are dif?cult to differentiate from normal age-associated
cognitive decline. More recently, studies suggest that a con

dition termed mild cognitive impairment (MCI) represents

US 7,851,172 B2
3

4

prodromal AD and if diagnosed early represents the best
opportunity for pharmaceutical intervention. The clinical cri

met With limited success, further restricting their Widespread

teria used for diagnosis of MCI are those of Petersen et al.

A Wide spectrum of other aberrations, other than NTP, Tau
and AB, has been reported in AD patient CSF. Many of the
identi?ed (protein sequence con?rmed) CSF markers

adoption into clinical practice.

(Arch Neurol 56:303-308 (1999) and include: 1) memory
complaints corroborated by an informant, 2) objective
memory impairment for age and education, 3) normal general

reported herein have been shoWn to be either increased or
decreased in AD patients versus normal individuals. For

cognitive function, 4) intact activities of daily living, and 5)

example, the protein Ubiquitin is knoWn to complex With
hyperphosphorylated Tau during maturation of NFTs in the
brains of AD patients (Iqbal et. al. J Neural Transm Suppl.
53:169-80 (1998)). Ubiquitin levels in CSF ofAD and neu
rological control groups have been shoWn to be signi?cantly
higher than those of non-neurological aged controls (Wang et.
al. Acta Neuropathol (Berl). 82(1):6-12 (1991); Kudo et. al.

the subject does not meet criteria for dementia.
Further complicating diagnosis and treatment of AD is the
lack of a reliable biomarker that speci?cally identi?es AD

subjects, particularly early in the prodromal stage of the dis
ease (MCI).

In vieW of the magnitude of the public health problem
posed by AD, considerable research efforts have been under
taken to elucidate the etiology of AD as Well as to identify

biomarkers, characteristic proteins or metabolites objectively

Brain Res. 639(1):1-7 (1994)).
The acute phase/in?ammatory protein alpha(1)-antichy

measured as an indicator of pathogenic processes, that can be

motrypsin (ACT) is overproduced in the AD brain. ACT also

used to diagnose and/ or predict Whether a person is likely to

can promote the formation of, and is associated With, neuro

develop AD.

toxic amyloid deposits (Potter et. al. Neurobiol Aging. 22(6):

Most studies of biomarkers of AD have focused on mea

20

923-30 (2001)). The levels ofACT in both serum and CSF are

surement in the cerebrospinal ?uid (CSF). CSF is produced in

signi?cantly and speci?cally higher in patients With AlZhe

the choroid plexus, a leaf like structure that projects into the
lateral, third and fourth ventricles of the brain (Huhmer et al.
Disease Markers 22:3-26 (2006)) and is in direct contact With
the extracellular space of the brain. Because of its intimate

imer-type dementia than in control subjects (Matsubara et. al.
AnnNeurol. 28(4):561-7(1990)). There is a particularly close
association of increases in CSF-ACT With late onset AD
25

(Harigaya et. al. Intern Med. 34(6):481-4 (1995)).

ChromograninA (CrA) is the major protein of large dense

contact With the brain, pathogenic changes in the brain that
result in alterations in proteins/peptides Would likely be

core synaptic vesicles and may be of value as a biochemical

re?ected in the CSF.

marker for synaptic function in AD. One report described no

A number of US. patents and published applications relate
to methods for diagnosing AD, including US. Pat. Nos.

difference betWeen AD, vascular dementia, and age-matched

4,728,605, 5,874,312, 6,027,896, 6,114,133, 6,130,048,
6,210,895, 6,358,681, 6,451,547, 6,461,831, 6,465,195,

control groups except When comparing a familial subtype
(AD Type I) With controls Where there Was a statistically
signi?cant elevation of CSF CrA in the diseased individuals

6,475,161, 6,495,335, 2005/0244890, and 2005/0221348.

(BlennoW et. al. Dementia. 6(6):306-11 (1995)).

Additionally, a number of reports in the scienti?c literature
relate to certain biochemical markers and their correlation/

30

35

association With AD, including Fahnestock et al., 2002, J.
Neural. Transm. Suppl. 2002(62):241-52; Masliah et al.,
1195, Neurobiol. Aging 16(4):549-56; PoWer et al., 2001,

proteome analysis of CSF by tWo-dimensional electrophore
sis (2D-gel) has shoWn a signi?cant increase of [32M in AD

patients (Davidsson et al., Neuroreport, 13:611-615 (2002)),

Dement. Geriatr. Co gn. Disord. 12(2): 1 67-70; and Burbach et

al., 2004, J. Neurosci. 24(10):2421-30. Additionally, Li et al.
(2002, Neuroscience 113(3):607-15) and Sanna et al. (2003,
J. Clin. Invest. 111(2):241-50) have investigated Leptin in
relation to memory and multiple sclerosis, respectively.
Three different biomarkers in CSF have been particularly
Well documented: neuronal thread protein, tau (total; T-tau

Beta-2-Microglobulin ([32M) is an initiator of in?amma
tory responses modulated by interferons and certain cytok
ines (Hoekman et.al. Neth. J. Med. 28:551-557 (1985)). A

40

and more recently these results Were con?rmed by SELDI

analysis (Carrette, O. et. al., Proteomics, 3:1486-1494

(2003)).
Transthyretin (TTR) has been shoWn to interact with A6,

possibly preventing amyloid formation in biological ?uids
45

and in the brain. (TsuZuki et al., Neurosci Lett, 10:171-174

and various phosphorylated forms; P-tau) and derivatives of

(2000)). One identi?ed TTR isoforrn Was shoWn to be

amyloid precursor protein (APP) including A640 and A642.

increased inAD-CSF using 2D gel analysis of a small number

Neuronal thread protein is described to be overexpressed in

ofAD and control patients (Davidsson, supra.). HoWever, this
result con?icts With other reports shoWing a clear decrease of

brain neurons in AD patients. A quantitative test for measur

ing levels of a speci?c type of neuronal thread protein (AD7c
NTP) in CSF and urine has been developed. Quite a number

50

Riisoen et. al. Acta Neurol Scand. 78(6):455-9 (1998)). This
decrease is also negatively correlated With the senile plaque
(SP) abundance (Merched et. al. FEBS Lett. 425(2):225-8

of studies have evaluated CSF-tau as an ante-mortem marker

for AD mainly using enZyme-linked immunoabsorbent
assays (ELISA) as the measurement assay. In past studies,
total tau (T-tau) has been measured although there is an

TTR in CSF from AD patients compared With controls (Serot
et. al. J Neurol Neurosurg Psychiatry. 63(4):506-8 (1997);

55

increasing body of literature also describing the analysis of

(1 998)).
Cystatin C, a cysteine protease inhibitor, has been impli

phosphorylated (P-tau) variants of the same protein involved

cated in the neurodegenerative and repair processes of the

in the formation of NFTs. ELISAs that can distinguish

nervous system, and the deposition of the same protein
together With beta amyloid peptide Was found as cerebral

betWeen the major form ofA[3 ending at amino acid 40 (A640)
and the senile plaque forming species ending at position 42
(A642) have also been developed and evaluated extensively
for CSF analysis. These three assays, either used individually,

60

length Cystatin C Was found as a CSF marker for AD in a

previous SELDI pro?ling study (Carrette, supra.). A relative

or in the case of tau and AB 42, in combination, have not

demonstrated the required sensitivity and speci?city values
for routine clinical use, particularly for early diagnosis and
discrimination betWeen AD and other non-AD dementias. In
addition, attempts to measure tau andA[342 in blood have been

amyloid angiopathy (CAA) in different types of dementias
(Levy et.al. J. Neuropathol. Exp. Neurol. 60:94-104). Full
blood-brain barrier (BBB) dysfunction is associated With AD
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among very elderly individuals. The CSF/ serum albumin
ratio can be used as a measure of BBB function. Mean CSF/

serum albumin ratio has been reported to be higher in all
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dementias studied, including AD, than in nondemented indi
viduals (Skoog et al, Neurology. 50:966-71 (1998)).

Another embodiment of the present invention comprises
qualifying a neurodegenerative disease, including AD, in a
subject, comprising measuring a level of a protein complex
biomarker of the present invention.

Transferrin (TF) plays a role in anti-oxidant defense in
serum and is also produced in the brain Where its role in
oxidative stress is unclear. A study on DoWn’s syndrome

In the above and other embodiments of the present inven
tion, the measured level of the biomarker is correlated With
neurological disease. In embodiments, this may be accom
plished by comparing the measured amount to a reference

patients suffering from progressive dementia shoWed
decreased levels of TF When compared to age-matched con
trols With no neurological disease (Elovaara Acta Neurol

Scand. 69(5):302-5(1994)).

value for the biomarker. The reference value can be obtained

Prostaglandin-D-Synthase (PDS) functions to convert
prostaglandin H2 to prostaglandin D2 and has been identi?ed
in several studies of CSF (Harrington et al. Appl Theoret
Electrophor 3:229-34 (1993); Hiraoka et al. J ChormatogrA
802:143-48 (1998); Kiraoka et al. Electorphorsis 22:3433
3437 (2001); KaWashima Mod. Pathol 14:197-201 (2001);

by measuring an amount of the biomarker in age-matched
control subjects that are not affected by the disease, or that are
free of the disease.

Another embodiment of the present invention comprises
monitoring the e?icacy of a treatment method of a neurode

generative disease, including AD, comprising measuring a
level of a protein complex biomarker of the present invention.
In embodiments, the e?icacy of treatment is measured by
monitoring levels of the biomarker in the subject compared to
a reference, and/or compared to other previous tests of the

Mase et al. Neurosci Lett 270:188-190; Mase Neurosci Res

47:455-459 (2003); Melegos et al. Prostaglandins 54:463
474 (1997)). Additionally, PDS demonstrates altered iso
forms in neurologic disorders including AD and Parkinson’ s
disease.
The present inventors have addressed the above-identi?ed

20

subject.

25

In embodiments of the present invention, the biomarker of
the present invention includes a complex comprised of a
transthyretin molecule and a prostaglandin-H2 D-isomerase
molecule.
Accordingly, one aspect of the present invention is a

needs by identifying a protein-protein complex that is present
in AD and MCI CSF and not age-matched control subjects.
Additionally, the present inventors have invented a diagnostic
test based on the detection of the protein-protein complex that
identi?es AD and MCI subjects With a high degree of speci

method of aiding diagnosis, or diagnosing a neurological
disorder, comprising comparing a measured level of a biom

?city. Levels of these protein-protein complexes can serve as

arker that comprises transthyretin and prostaglandin-H2

biomarkers to preferentially identify subjects With AD from
age-matched control subjects or subjects With other neuro
logic disorders. In addition, these biomarker complexes can

30

D-isomerase in a biological ?uid sample from an individual to
a reference level for the biomarker.

35

In other aspects, the above method further comprises the
step of managing the individual treatment based on the status.
For example, if measurement of the biomarker correlates With
the presence of AlZheimer’s disease, then managing treat
ment comprises administering a drug to sloW the progression

be used to identify subjects With mild cognitive impairment
(MCI), the earliest clinical manifestation of AD.
The diagnostic test of the present invention is of consider
able interest and bene?t because of its ability to identify

subjects With AD, particularly early in the progression of the

of the disease. Further measurements can be compared to the
previous measurements, or the standard to monitor the pro

disease (MCI). The tests of the present invention may also be
used to monitor e?icacy of treatment.

gression of the disease.
In a further aspect of the invention, the method further

SUMMARY OF THE INVENTION
40

As indicated herein, an embodiment of the present inven
tion provides a method for the diagnosis of MCI and AD or

methods of aiding in the diagnosis of neurological disorders,
including AD, by quantifying the amount of a protein-protein
complex-based biomarker in a biological ?uid sample of the
subject, such as a cerebrospinal ?uid, and comparing the

comprising a solid support comprising at least one capture
reagent attached thereto, Wherein the capture agent binds one
45

invention. The kit also contains a second reagent to interact

to measure levels of the second protein.

Other features, objects, and advantages of the invention

diagnosis, or to diagnose the disease in the individual. The

and its various embodiments Will become apparent from the

protein complex-based biomarkers are differentially present
in subjects having a neurological disease, including AD, ver

instant disclosure, including the detailed description,
examples, and claims.
BRIEF DESCRIPTIONS OF THE DRAWINGS
55

FIG. 1 is a graph shoWing levels of the protein complex
biomarker measured as ng/ml complexed transthyretin in
ventricular CSF from subjects With non-AD neuropatholo

a?llicted With a neurological disease, including AD, the
method comprising measuring a level of a protein complex
biomarker of the present invention.
Another embodiment of the present invention is a method

gies, MCI, EAD, LAD and age-matched control subjects.
60

comprising monitoring the progression of a neurodegenera
tive disease, including AD, comprising measuring a level of a
protein complex biomarker of the present invention.
Another embodiment of the present invention comprises
monitoring the e?icacy of a treatment method of a neurode

generative disease, including AD, comprising measuring a
level of a protein complex biomarker of the present invention.

component of the biomarker protein complex of the present

With the second portion of the trapped complex and reagents

measured amount With a reference value for the biomarker.
The information thus obtained may be used to aid in the

sus subjects free of the disease, or subjects having a different
form of dementia.
One embodiment of the present invention is a method of
diagnosing or assessing the likelihood that a patient is

comprises measuring the biomarker after treatment has
begun, to monitor the progression of the disease.
In still another aspect, the present invention provides a kit

65

FIG. 2 is a graph shoWing a statistically signi?cant positive
correlation exists betWeen levels of complexed transthyretin
as a measure of the protein complex and Braak staging scores,
a measure of NET pathology (higher Braak scoreimore
severe pathology).
FIG. 3 is a graph shoWing individual concentrations of the

protein complex biomarker measured as ng/ml complexed
transthyretin in CSF samples from living probable AD and

US 7,851,172 B2
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age-matched control subjects. All control subjects (N:13)

Psychiatr. Res 1975; 12:1289-198) score or Would achieve a
MMSE score in the range of 25-30. A “Normal” individual is
generally age-matched Within a range of 5 to 10 years, includ
ing but not limited to an individual that is age-matched, With
the individual to be assessed.

except for 1 showed levels of the protein complex beloW the

minimum detection limit (mean:SEM:3.6:0.7 ng/ml).
FIG. 4 is a graph showing meanzSEM levels of the biom

arker protein complex measured as ng/ml complexed tran
sthyretin in lumbar CSF from living probable AD and age
matched control subjects.
FIG. 5 is a graph shoWing levels of the protein complex
signi?cantly negatively correlate With mini mental status
examination (MMSE) scores (loWer MMSE4diminished

An individual With “mild cognitive impairment” is an indi
vidual Who meets the folloWing clinical criteria of amnestic

MCI (Petersen et al. Arch Neurol 56:303-308 (1999): 1)

memory complaints corroborated by an informant, 2) objec
tive memory impairment for age and education, 3) normal

cognitive function).

general cognitive function, 4) intact activities of daily living,

FIG. 6 is a diagram shoWing a sandWich ELISA protocol of
the present invention.

and 5) the subject does not meet criteria for dementia.
An “individual With moderate (early) AD (EAD)” is an
individual Who demonstrate the folloWing criteria: 1) a

DESCRIPTION OF THE INVENTION

decline in cognitive function for a previous higher level, 2)
declines in one or more areas of cognition in addition to

In embodiments of the present invention, the protein com
plexes of the preset invention are markers for neurodegenera

tive diseases, including mild cognitive impairment and
AlZheimer’s disease. Levels of the protein complex of the
present invention are elevated in bodily ?uids, including cere
brospinal ?uid, as compared to normal, non-demented age
and gender-matched controls and comparatively demented
patients. Thus, the biomarkers of the present invention can be
used to classify a subject sample as having MCI, AlZheimer’s,

20

for probable AD (McKhann et al. Neurology 34:939-48

(1 984).
25

or normal.

DEFINITIONS

As used herein, the terms “AlZheimer’s patient”, “AD
patient”, and “individual diagnosed With AD” all refer to an

individual Who has been diagnosed WithAD or has been given
a probable diagnosis of AlZheimer’s Disease (AD).
When used herein, methods for “aiding diagnosis” refer to
methods that assist in making a clinical determination regard

30

35

not be conclusive With respect to the de?nitive diagnosis.

Accordingly, for example, a method of aiding diagnosis of
AD can comprise measuring the amount of one or more AD
40

When used herein, the term “predicting” refers to making
a ?nding that an individual has a signi?cantly enhanced prob

ability of developing a certain neurological disease.
As used herein, the phrase “neurological disease” refers to
a disease or disorder of the central nervous system. Neuro

45

ease, amyotrophic lateral sclerosis (ALS), mild cognitive

plural (i.e., can mean one or more) unless indicated other
Wise.

As indicated herein, the present invention involves biom
arkers. A biomarker is a characteristic biomolecule Which is
differentially present in a sample taken from a subject of one
55

have been manipulated in any Way after their procurement,
such as by treatment With reagents, solubiliZation, or enrich
ment for certain components, such as proteins or polynucle
otides.

phenotypic status (e.g., having a disease) as compared With
another phenotypic status (e.g., not having the disease). A
biomarker is differentially present betWeen different pheno
typic statuses if the mean or median expression level of the
biomarker in the different groups is calculated to be statisti

60

cally signi?cant. Biomarkers, alone or in combination, pro
vide measures of relative risk that a subject belongs to one
phenotypic status or another. Therefore, they are useful as

Mammals include, but are not limited to, humans, primates,

farm animals, sport animals, rodents and pets.

markers for disease (diagnostics), therapeutic effectiveness
of a drug (theranostics) and drug toxicity.

A “Normal” individual or sample from a “Normal” indi

vidual as used herein for quantitative and qualitative data

State Examination (MMSE) (referenced in Folstein et al., J.

large number of samples, such as from AD patients or normal

As used herein, a , an”, and “the” can mean singular or
50

can be used in a diagnostic or monitoring assay. The de?nition
encompasses Whole blood, blood serum or blood plasma,

refers to an individual Who has or Would be assessed by a
physician as not having AD or MCI, and has an Mini-Mental

vidual sample value, such as for example, a value obtained
from a sample from the individual WithAD, MCI or cognitive
impairment, but at an earlier point in time, or a value obtained
from a sample from an AD patient other than the individual

ing the sample to be tested.

impairment (MCI) and frontotemporal dementia.

An “individual” is a mammal, more preferably a human.

As used herein, a “reference value” can be an absolute
value; a relative value; a value that has an upper and/ or loWer
limit; a range of values; an average value; a median value, a
mean value, or a value as compared to a particular control or
baseline value. A reference value can be based on an indi

individuals or based on a pool of samples including or exclud

neurodegenerative disorders such as AD, Parkinson’s dis

cerebrospinal ?uid (CSF), urine and other liquid samples of
biological origin. The de?nition also includes samples that

or more symptoms of AD, stabiliZation of the symptoms of
AD (e. g., failure to progress to more advanced stages ofAD),
and delay in progression (i.e., Worsening) of one or more
symptoms of AD.

being tested, or a “normal” individual, that is an individual not
diagnosed With AD. The reference value can be based on a

logical diseases include multiple sclerosis, neuropathies, and

As used herein, “biological ?uid sample” encompasses a
variety of ?uid sample types obtained from an individual and

As used herein, the term “treatment” refers to the allevia
tion, amelioration, and/or stabiliZation of symptoms, as Well
as delay in progression of symptoms of a particular disorder.
For example, “treatment” ofAD includes any one or more of:
elimination of one or more symptoms ofAD, reduction of one

ing the presence, or nature, of the AD or MCI, and may or may

biomarkers in a biological sample from an individual.

memory, 3) a clinical dementia rating scale score of 0.5 to 1,
and 4) a clinical examination that excluded other causes of
dementia.
An “individual With severe (late stage) AD (LAD)” is an
individual Who meets the standard clinical diagnostic criteria
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In this invention, novel biomarkers are discussed that are

differentially present in subjects having neurodegenerative
diseases such as AD versus subjects free of the disease. In
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addition, the present invention provides methods of using the
protein complex-based biomarkers to qualify AlZheimer’s

linked immunoassay (ELISA) is utiliZed that traps a ?rst
component of the complex and probes for a second compo
nent. For example, in embodiments of the present invention,
the sandWich ELISA traps a PDS and probes for the second
component, TTR.
Preliminary analysis of a small number of ventricular CSF

disease in a subject.
The biomarker complex Was discovered using molecular

Weight fractionation to isolate proteins betWeen about 50 and
100 kDa, 2-dimensional electrophoresis and MALDI mass
spectrometry for protein identi?cation. Protein identi?cation

specimens from MCI, EAD, LAD and age-matched control
subjects shoWed the complex Was signi?cantly elevated in
MCI (122124 ng/ml), EAD (120117 ng/ml) and LAD

Was based on database searches using SEQUESTTM. Based
on initial studies of proteins isolatedbetWeen 50 and 100 kDa,
several proteins of molecular Weight less than 50 kDa Were

(115120 ng/ml) subjects compared to age-matched controls

identi?ed. Using l-dimenstional electrophoresis and Western

(<5 ng/ml). Additionally, CSF from subjects With other neu
rologic disorders including Parkinson’s disease (PD), diffuse

blot analysis, a band of ~55 kDa Was identi?ed that Was

LeWy body disease (DLB), progressive supranuclear palsy

immunopositive for both prostaglandin-d-synthase and tran
sthyretin suggesting a protein complex or aggregate. Based

(PSP) and frontotemporal dementia (FTD) shoWed concen
trations <5 ng/ml, suggesting a high degree of sensitivity/
speci?city for the diagnosis of AD. Preliminary analysis of

on these observations, an embodiment of the present inven

tion, an enzyme linked immunoassay (ELISA) Was devel

oped that traps prostaglandin-D-synthase and probes for and

lumbar CSF specimens from a small number of living, prob
able AD and age-matched controls shoWed that the protein

quanti?es attached transthyretin.

complex is present in probable AD subjects (about 37.5162

More speci?cally, to interrogate CSF for novel biomarker

proteins, the present inventors subjected ventricular CSF

20

ng/ml) and that it is about 100% sensitive and about 93%

obtained at autopsy from late stage AD (LAD) and age

speci?c in the identi?cation of AD subjects compared to

matched control subjects to molecular Weight (MW) fraction
ation and 2-dimensional electrophoresis. Mass spectrometry

age-matched controls (about <5 ng/ml) With minimal overlap
betWeen the subject populations.

of these molecular Weight fractions shoWed the presence of a

series of proteins in MW fractions higher than expected
Which among other scenarios, suggested that these proteins

25

ing TTR and PDS, may serve as a sensitive and speci?c
diagnostic biomarker ofAD and more importantly appears to

may be part of an aggregate or complex.

identify subjects With MCI.

Using this approach, the present inventors identi?ed dif

ferentially expressed proteins in LAD CSF, including beta-2

microglobulin, carbonic anhydrase, cystatin C, copper/Zinc
superoxide dismutase (Cu/Zn SOD), phosphytidylethanola
mine binding protein, plasma retinol binding protein, pros
taglandin-d-synthase (PDS), serotransferrin and transthyretin

30

level for a AD biomarker may vary, depending on aspect of

35

homotetrameric TTR Would be expected to be in the less than
about 50 kDa fraction. Western blot analysis of fractionated
CSF samples shoWed a band of ~55 kDa that Was immunopo
sitive for Cu/Zn SOD, TTR and PDS. In addition to the higher

molecular Weight band, bands corresponding to the native
monomeric proteins Were also observed using each antibody

(MW ~16 kDa) shoWed a signi?cant elevation in LAD CSF
although there Was considerable overlap of individual subject
values betWeen the tWo populations, limiting the usefulness
of the native proteins as a diagnostic biomarker. In contrast,
levels of the ~55 kDa band immunopositive for PDS and TTR
shoWed signi?cant differences betWeen LAD and control

individuals including AD patients. In some instances, the
predetermined reference level is derived from (e.g., is the
40

For MCI diagnosis methods (i.e., methods of diagnosing or

aiding in the diagnosis of MCI), the reference level is typi
45

MCI and/or AD patients. In some instances, the predeter
mined reference level is derived from (e.g., is the mean or
50

AD CSF compared to controls. Based on identi?cation of

components of the protein complex, a sandWich enZyme

median of) levels obtained from an age-matched population.
For AD monitoring methods (e.g., methods of diagnosing
or aiding in the diagnosis of AD progression in an AD
patient), the reference level may be a predetermined level,

55

such as an average of levels obtained from a population that is
not a?llicted With AD or MCI, a population that has been

diagnosed With MCI or AD, and, in some instances, the ref
erence level can be a mean or median level from a group of

individuals including MCI and/or AD patients. Alternately,
60

related manner.

To determine if the protein-protein complex is present in
lumbar CSF, a small number of samples from living, probable
AD and age-matched control subjects Was analyZed and
shoWed similar trends With signi?cant elevations in probable

cally a predetermined reference level, such as an average of
levels obtained from a population that is not a?llicted WithAD
or MCI, but in some instances, the reference level can be a
mean or median level from a group of individuals including

compared to age-matched controls With virtually no overlap
betWeen the populations. Additionally, analysis of ventricular
CSF specimens from MCI, early AD (EAD) and LAD sub
jects shoWed the complex Was signi?cantly elevated in MCI
subjects and that levels increased in a disease-progression

mean or median of) levels obtained from an age-matched

population.

subjects With minimal overlap betWeen the 2 populations.
Calculation of the product of staining intensity using anti
TTR and anti-PDS shoWed about a 10 fold increase in LAD

such as an average of levels obtained from a population that is
not a?llicted With AD or MCI, but in some instances, the
reference level can be a mean or median level from a group of

suggesting loss of native protein from the complex folloWing
addition of denaturing gel loading buffer.
Comparison of levels of native monomeric proteins
shoWed no signi?cant differences betWeen LAD and control
subjects for PDS or Cu/Zn SOD. Levels of monomeric TTR

Reference Levels
The reference level used for comparison With the measured

the invention being practiced, as Will be understood by one of
ordinary skill in the art. For AD diagnosis methods, the “ref
erence level” is typically a predetermined reference level,

(TTR). Under normal conditions, most of the observed dif

ferentially expressed proteins except serotransferrin and

Such data suggest that levels of a unique protein complex
consisting of embodiments of the present invention, includ

the reference level may be a historical reference level for the
particular patient (e.g., a level that Was obtained from a
sample derived from the same individual, but at an earlier

point in time). In some instances, the predetermined reference
level is derived from (e.g., is the mean or median of) levels
65

obtained from an age-matched population.
For AD strati?cation methods (i.e., methods of stratifying
AD patients into mild, moderate and severe stages ofAD), the
reference level is normally a predetermined reference level
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that is the mean or median of levels from a population Which

12
plasma retinol-binding protein, phosphatidylethanolamine

has been diagnosed With AD or MCI (preferably a population

binding protein, carbonic anhydrase 2, prostaglandin-H2

diagnosed With AD) In some instances, the predetermined

D-isomerase, and/or serotransferrin is identi?ed by probing

reference level is derived from (e. g., is the mean or median of)

the trapped protein.

levels obtained from an age-matched population.

In the correlating step, the amount of said protein biomar

Age-matched populations (from Which reference values

ker complex With a reference value in a control sample can be

may be obtained) are ideally the same age as the individual

compared. In embodiments, the control sample is from a
normal individual. The control sample can be compared With
a previous sample taken from a patient. Additionally, the
method can comprise comparing the control sample With the
?uid sample of the subject to determine the progression of the
mild cognitive impairment or the AlZheimer’s disease.
Preferably, the sample is cerebro spinal ?uid, Which can be
collected via a spinal tap.
In one aspect of the present invention, the process may be

being tested, but approximately age-matched populations are

also acceptable. Approximately age-matched populations
may be Within 1, 2, 3, 4, or 5 years of the age of the individual
tested, or may be groups of different ages Which encompass
the age of the individual being tested. Approximately age

matched populations may be in 2, 3, 4, 5, 6, 7, 8, 9, or 10 year
increments (eg a “5 year increment” group Which serves as
the source for reference values for a 62 year old individual

might include 58-62 year old individuals, 59-63 year old
individuals, 60-64 year old individuals, 61-65 year old indi
viduals, or 62-66 year old individuals).
Comparing Levels of AD Biomarkers
The process of comparing a measured value and a refer

used as a method of monitoring the progression of a neuro
logical disorder. In this aspect, a ?rst measured level of a

biomarker complex of the present invention is compared With
20

appropriate to the type of measured value and reference value
for the AD biomarker at issue. For example, ‘measuring’ can

said ?rst measured level of the biomarker complex. FolloW
ing this comparison, the progression of the disease based on

be performed using quantitative or qualitative measurement
techniques, and the mode of comparing a measured value and

25

a reference value can vary depending on the measurement

technology employed. The example, the measured values
used in the methods of the invention Will most commonly be
quantitative values (e.g., quantitative measurements of con
centration, such as nanograms of AD biomarker per milliliter
of sample, or absolute amount). As With qualitative measure

30

cal data, by inspecting representations of the data (e.g.,

prostaglandin-H2 D-isomerase, beta-2-microglobulin, cysta

inspecting graphical representations such as bar or line

graphs).

35

As an example, a measured value is generally considered to
be substantially equal to or greater than a reference value if it
is at least about 95% of the value of the reference value (e.g.,
a measured value of 1.71 can be considered substantially
equal to a reference value of 1.80). A measured value is
considered less than a reference value if the measured value is
less than 95% of the reference value (e. g., a measured value of
1.7 can be considered less than a reference value of 1.80).
One embodiment of the present invention is a method for

40

quantifying a neurodegenerative disorder in a patient that

45

anti-human transthyretin), and a horseradish peroxidase con

50

transthyretin, prostaglandin-H2 D-isomerase, beta-2-micro
globulin, cystatin C, superoxide dismutase [CuiZn], plasma

retinol-binding protein, phosphatidylethanolamine-binding
anhydrase

2,

In embodiments, the solid support is a 96 Well polystyrene
microtiter plate. In others, the solid support is coated With

the second component of the protein complex (i.e., rabbit

In embodiments of the present invention, the biomarker com

carbonic

tin C, superoxide dismutase [CuiZn], plasma retinol-bind
ing protein, phosphatidylethanolamine-binding protein, car
bonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or
serotransferrin protein.

anti-prostaglandin-D-synthase for protein capture.
In embodiments, the second primary antibody recogniZes

comprises obtaining a ?uid sample from the subject, and
measuring a protein biomarker complex in said ?uid sample.

protein,

the ?rst and second measured level of said biomarker com
plex can be determined.
Another aspect of the present invention is a diagnostic kit
for quantifying AlZheimer’s disease status. The kit may com
prise a solid support coated With an antibody to capture at
lease one of a protein complex selected from prostaglandin

D-synthase and/or transthyretin; and a second primary anti
body to recognize the second component of the protein com
plex, the second component selected from a transthyretin,

ments, the comparison can be made by inspecting the numeri

prises at least one of transthyretin and/or prostaglandin-H2
D-isomerase, and at least one second protein selected from

a reference level of the biomarker complex, and after alloWing
a period of time to pass, comparing a second measured level
of the biomarker complex to said reference level and/or to

ence value can be carried out in any convenient manner

jugated secondary antibody against the species used to gen
erate the second primary antibody (ie goat anti-rabbit), TMB
color reagent and stopping solutions.
With respect to embodiments of the present invention, FIG.
1 shoWs an embodiment of the present invention Where analy

sis of ventricular CSF from autopsy-con?rmed MCI (N:5),
EAD (N:4), late stage AD (N:9) and age-matched control
subjects (N:8) shoWs that presence of the protein complex
measured as ng/ml Transthyretin identi?es MCI and AD sub

prostaglandin-H2

ment or AlZheimer’s disease status is determined by correlat

jects With a high degree of speci?city (100%) and sensitivity
(AD; 100%; MCI 80%).

ing the obtained measurement With standards.
In a preferred embodiment of the present invention, the

FIG. 2 shoWs a statistically signi?cant positive correlation
betWeen levels of the protein complex and Braak staging

D-isomerase, and/or serotransferrin. Mild cognitive impair

protein biomarker complex comprises transthyretin and pros
taglandin-H2 D-isomerase.

55

scores, a measure of NFT pathology. Analysis of ventricular
60

In another embodiment of the present invention, the mea

suring step comprises trapping by enZyme linked immun

speci?city of the biomarker complex for AD and MCI.
Doubly blinded analysis of lumbar CSF from living AD

osorbent assay (ELISA) at least one of transthyretin and/or

prostaglandin-H2 D-isomerase; and probing for a second,
different protein selected from the group consisting of at least
one of transthyretin, prostaglandin-H2 D-isomerase, beta-2

microglobulin, cystatin C, superoxide dismutase [CuiZn],

CSF from non-AD pathologies including diffuse LeWy body
disease (N:5), Parkinson’s disease (N:2), parasupranuclear
palsy (N:2) and frontotemporal dementia (N:2) shoWs 100%
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(N:15) and age-matched control subject (N:14) shoWs 100%
sensitivity and 93% speci?city in identi?cation of AD and

control subjects (FIG. 3).
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FIG. 4 shows a statistically signi?cant 10 fold increase in

ventions. The course of disease may be determined based on

levels of the protein complex measured as ng/ml transthyretin

comparisons. Similarly, this method is useful for determining

in probable AD subjects.

the response to treatment. If a treatment is effective, then the

Additionally there is a statistically signi?cant negative cor
relation betWeen levels of the protein complex measured as
ng/ml transthyretin and mini-mental status examination
(MMSE) scores, a measure of cognitive function (FIG. 5).
Correlation analysis shoWs there is no statistically signi?
cant relationship betWeen age and levels of the protein com

biomarkers Will trend toWard normal, While if treatment is
ineffective, the biomarkers Will trend toWard disease indica
tions.
An embodiment of the present invention is methods of
identifying complexes that can be used as biomarkers of the

plex. Additionally, there are no sex related differences.
Use of Modi?ed Forms of a Biomarker

aiding in diagnosis, stratifying, assessing risk, monitoring

present invention, the biomarkers being useful for diagnosis,
and/or predicting a neurological disease. Using methods

It has been found that proteins and protein complexes
frequently exist in a sample in a plurality of different forms

described herein, protein spots representing different proteins

characterized by differences in phosyphorylation, glycosyla

can be identi?ed as signi?cantly different betWeen LAD and

tion and oxidative modi?cation including aldehyde modi?
cation by compounds such as levuglandin, HNE and acrolein.

fractionation of ventricular CSF specimens from 5 LAD and

control subjects. In one example, molecular Weight (MW)

Because the antibodies are able to recogniZe the protein

5 age-matched controls canbe separated into fractions greater

regardless of posttranslational modi?cations the assay may

than and less than about 50 kDa and subjected to 2-dimen

be carried out as described. All the protein and protein com
plex modi?cations that Would be understood by one of ordi
nary skill in the art are Within the scope of the present inven
tion.
Of course, embodiments of the present invention includes

various nomenclature forms. For example, cystatin C is also
knoWn as neuroendocrine basic polypeptide, Gamma-trace,

20

as signi?cantly different betWeen LAD and control subjects.

Examples of the proteins identi?ed Were beta-2-microglobu

lin, cystatin C, Cu/Zn superoxide dismutase, transthyretin,

plasma retinol-binding protein, phosphatidylethanolamine
25

binding protein, carbonic anhydrase 2, prostaglandin-D-syn

30

thase, and serotransferrin. The present inventors found that
the majority of the proteins identi?ed in the greater than 50
kDa fraction normally Weigh less than 50 kDa and should
have been isolated in the lighter fraction. Based on this obser
vation, the present inventors determined the presence of a

Post-gamma-globulin. Transthyretin is also knoWn as preal

bumin, TBPA, TTR, ATTR. Plasma retinol-binding protein is
also knoWn as PRBP, RBP. Phosphatidylethanolamine-bind

ing protein is also knoWn as PEBP, prostatic binding protein,
HCNPpp, neuropolypeptide h3, Raf kinase inhibitor protein,

sional electrophoresis. Following a comparison of the gels,
protein spots representing different proteins Were identi?ed

RKIP. Carbonic anhydrase 2 is also knoWn as EC 4.2.1.1,

complex. To con?rm that the proteins are present as a com

Carbonic anhydrase II, Carbonate dehydratase II, CA-II, Car

plex, CSF samples from 8 LAD and 7 age-matched controls
are subjected to MW fractionation, freeZe dried, resuspended

bonic anhydrase C. Prostaglandin-H2 D-isomerase is also
knoWn as EC 5.3.99.2, Lipocalin-type prostaglandin-D syn

thase, Glutathione-independent PGD synthetase, prostaglan

35

din-D2 synthase, PGD2 synthase, PGDS2, PGDS, Beta-trace

in 30 pl PBS and subjected to Western blot analysis and
probed for PDS and TTR. Subject demographic data are
shoWn in Table 1, beloW.

protein, Cerebrin-28. Serotransferrin is also knoWn as trans

ferrin, siderophilin, beta-1-metal binding globulin.
Detection of Biomarkers for AlZheimer’s Disease
The biomarkers of this invention can be detected by any

TABLE 1
Sub'ect demographic data for ventricular CSF specimens.
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suitable method including Western blot analysis and ELISA

Mean 1

as described herein. ELISA is a preferred technique because

SEM

ofits ease of use.

Determination of Risk of Developing Disease
In one embodiment of the present invention is a method for

determining the risk of pro gressing from amnestic MCI to AD
in a subject. Biomarker amounts shoW signi?cant positive

Control
Non-AD

correlations With Braak staging scores that measure the

EAD
LAD

concentrations of the protein complex, MCI subjects With
higher levels Would be projected to advance to AD.
55

TTR

Age (y)

Sex

(hr)

Score

83.3 r 2.3
70.4 142*

4M/3F
7M/5F

3.4 r 0.4
4.7 r 1.6

I
II

89.8 :1.4*
89.5 r 2.7
81.6 r 2.0

2M/2F
1M/3F
4M/4F

4.2 r 1.8
2.8 r 0.7
3.1 r 0.1

IV*
V*
VI*

control
1.0
1.4

0.4
0.2

2.9 r 0.5*
3.7 r 0.3*
9.7 r 2.2*

There Were no signi?cant differences in age or postmortem

interval (PMI) betWeen LAD and control subjects. Median
Braak staging scores Were signi?cantly higher in LAD
(medianIVI) compared to controls (medianII). A use of the
monoclonal PDS antibody shoWed the presence of native
PDS (MW:21 kDa) and a strongly immunopositive band at

comparisons (i.e., control vs. MCI).
Determining Course (Progression/Remission) of Disease
In one embodiment, this invention provides methods for
determining the course of AlZheimer’s disease in a subject.
Disease course refers to changes in disease status over time,

~55 kDa that Was more strongly stained inAD specimens than

in controls. Stripping and reprobing the gels for TTR shoWed

including disease progression (Worsening) and disease

expected to decrease With appropriate pharmacologic inter

Braak

Staging Fold inc over

*p < 0.05

analysis of variance to compare disease progression related
differences. Post hoc testing Will be carried out for pairWise

regression (improvement). Over time, the amounts or relative
amounts (e.g., the pattern) of the biomarkers changes. For
example, the concentrations of biomarkers Would be

SEM PMI

Disorders
50 MCI

nation scores) that measure cognitive function. Based on the

Data Analysis
Results of the assay Will be compared statistically using

Mean :

SEM

complexed

Neurologic

degree of neuropathology (speci?cally NET) and signi?cant
negative correlations With MMSE (mini-mental status exami

Mean 1

Median

an immunopositive band corresponding to native TTR
65

(MW:16 kDa) and the band at ~55 kDa. To verify speci?city
of the antibodies, representative LAD CSF specimens Were
subjected to Western blot analysis using antibodies that had

been pretreated With representative immuniZing proteins.

US 7,851,172 B2
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To determine if the protein complex is present at early
stages of AD and is speci?c for AD, the present inventors
carried out Western blot analyses of ventricular CSF samples
from 4 subjects With MCI, 4 EAD subjects and 12 subjects
With non-AD neurologic diseases including PD (N:2), PSP
(N:2), DLB (N:5), and FTD (N:3). Table 1 shoWs subject

buffer). Color Was developed using 3,3',5,5'-tetramethylben
Zidine (TMB) color reagent folloWed by addition of stopping
solution. Absorbance Was read at 450 nm using a multi-Well

UV-Vis plate reader. Concentrations of TTR Were quanti?ed
using a calibration curve of knoWn concentrations of human

TTR (0 to 500 ng/ml) coated in triplicate on each plate.

demographic data. There Were no signi?cant differences in
age betWeen controls, LAD or EAD subjects. MCI subjects

To determine limits of detection (LOD) and mean correla

tion coef?cients using this approach, replicate analyses of

Were signi?cantly older than control subjects and subjects
With non-AD pathologies Were signi?cantly younger than
controls. Median Braak staging scores Were signi?cantly

plates). Calculation of correlation coef?cients shoWed a sta

higher in MCI (medianIIV), EAD (medianIV) and LAD

tistically

(medianIVI) subjects compared With controls (medianII).

(r:0.92:0.02) betWeen concentration and absorbance sug

standard solutions of TTR Were carried out using 0, 25, 50,

100, 250 and 500 ng/ml TTR in PBSN (6 Wells/plate; 3

signi?cant

(p<0.01)

positive

correlation

There Were no signi?cant differences in post mortem inter

gesting a good linearity of response over a Wide concentration

vals for any of the subjects. Measurement of staining intensity

range. Calculation of mean LOD shoWed a meanzSEM value

of the individual native proteins shoWed no signi?cant differ
ences betWeen LAD and control subjects for TTR although
PDS Was signi?cantly elevated in LAD CSF. HoWever, there
Was considerable overlap of individual subjects from the tWo
populations suggesting limited use of the native proteins as
biomarkers. Staining intensity of the 55 kDa band Was calcu
lated as % of control staining for each gel for each of the

of3.6:0.7 ng/ml.
To verify the ELISA described above provides similar
results to those observed using Western blot anlaysis, aliquots
of unprocessed ventricular CSF from subjects Were subjected
20

overlap of the subject populations.

antibodies. Because We hypothesized the amount of the com

plex and not the native proteins, is indicative of AD, the
present inventors calculated the product of the tWo percent
ages. Table 1 shoWs the meanzSEM product of the % control

to the ELISA in triplicate. Table 2, beloW shoWs results of the
analyses for individual subjects and shoWs that there is no

TABLE 2

25

Individual complexed TTR concentrations (ng/ml CSF) in ventricular CSF.

staining intensities for control, non-AD pathologies, MCI,
Non-AD

EAD and LAD subjects and shoWs a signi?cant disease pro

gression related increase in the protein complex With statis
tically signi?cant elevations of the complex in MCI, EAD and
LAD subjects compared With control subjects. To be an effec
tive biomarker of AD, the substance being studied in CSF
must be present in brain. To determine if the protein complex

Control
30

is present inAD brain, preliminary studies Were carried out to

determine if the protein complex could be detected in repre
sentative specimens of HPG from LAD and control subjects.
Specimens of HPG (N:4 LAD and 4 control) Were homog
eniZed in HEPES buffer and subjected to Western blot analy

35

<5 ng/rnl
<5 ng/rnl
<5 ng/ml
<5 ng/ml
<5 ng/ml
<5 ng/ml
<5 ng/ml

<5
<5
<5
<5
<5
<5
<5

ngrnl
ngrnl
ngml
ngml
ngml
ngml
ngml

<5 ng/ml

<5
<5
<5
<5
<5

ngml
ngml
ngml
ngml
ngml

<5 ng/ml

<5 ngml

SlS.

Preliminary confocal analyses of sections of HPG immu

40

Pathologies

MCI

EAD

LAD

93.0
110.0
93.0
192.0

175.0
139.5
93.0
74.0

205.0
61.0
27.5
46.5
74.0
141.0
262.5

122 1
23.7*

120.0 :17.3*

115.4 1196*

nostained for CNPase, a marker of oligodendrocytes or

GFAP, a marker of glia concurrently With TTR and PDS shoW

*p < 0.05

PDS is primarily associated With CNPase-positive oligoden
drocytes Whereas TTR is more strongly associated With

GFAP-positive astrocytes. Comparison of LAD and control
staining shoWs considerably higher levels of TTR and PDS in
LAD brain compared to age-matched controls.
Based on the Western blot analyses, the present inventors
initiated development of an enZyme linked immunoassay
(ELISA) based on capture of one component of the complex
and quanti?cation of another component from small volumes

45

dent’s t-test shoWed concentrations of complexed TTR Were
50

blot analyses, there Were no differences betWeen control and

ELISA conditions, a serial dilution matrix analysis Was car

ried out using antibody concentrations betWeen 0 and 1000

ng/ml PBS containing 0.05% sodium aZide (PBSN). We

trapped complex Were quanti?ed using rabbit anti-TTR
raised against amino acids 1-147 of human TTR (1 ug/ml in

blocking buffer) and horseradish peroxidase conjugated goat
anti-rabbit secondary antibody (1:1000 dilution/blocking

signi?cantly elevated in MCI, EAD and LAD CSF compared
to control subjects (Table 2). As Was observed for Western
non-AD pathologies. Although these data represent a small
number of subjects, it demonstrates 100% sensitivity and
100% speci?city for the identi?cation of subjects at all stages

of CSF. Using standard techniques for the optimiZation of

tested both anti-TTR and anti-PDS as the trap antibody With
the other as the probe antibody. Based on these studies an
ELISA Was established in Which 96 Well microtiter plates
Were coated overnight with mouse anti-PDS raised against
recombinant human PDS at 1 ug/ml PBSN. The plates Were
rinsed and blocked for 1 hr using 5% dry milk/15% normal
goat serum in PBSN and incubated With unprocessed CSF.
Following 5 Washes of PBSN, levels of TTR present in the

Control subjects and those With non-AD pathologic disor
ders shoWed levels beloW detection limits (<5 ng/ml) Whereas
all MCI, EAD and LAD subjects shoWed values considerably
higher than the LOD. Comparison of mean values using Stu

55
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of AD including MCI. Because a suitable biomarker of AD
should correlate With some aspect of the neuropathology,
correlation analyses Were carried out for all subjects compar
ing Braak staging score, a measure of NET pathology, and

levels of complexed TTR and shoWed a statistically signi?
cant (p<0.01) positive correlation (r:+0.66) betWeen levels of
complexed TTR and Braak score. Based on these data, use of

a protein complex consisting of TTR and PDS appears to be
e?icient in the identi?cation ofAD subjects at all stages ofAD

including MCI in ventricular CSF specimens.
65

To be effective as a diagnostic biomarker for AD, the 55

kDa protein complex identi?ed must be present at a quanti
?able level in a relatively easily sampled ?uid such as lumbar

US 7,851,172 B2
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CSF. To determine if the protein complex is present in lumbar
CSF, specimens Were obtained from 15 living probable AD
subjects and 14 age-matched control subjects and Were ana
lyZed in a doubly blinded fashion using the ELISA described

The folloWing non-limiting examples are presented as
being exemplary of the present invention, and are not to be
construed as limiting thereof.
EXAMPLE 1

above. Table 3, beloW, shoWs subject demographic data.
There Were no signi?cant differences in age betWeen AD and
control subjects. Mean MMSE scores Were signi?cantly

Determining Presence of Biomarker in Sample

(p<0.05) loWer in AD subjects (19312.4) compared to con

CSF samples Were collected from 6 MCI, 4 EAD, 9 LAD
and 8 age-matched control subjects at autopsy from the lateral

trols (29210.2).

ventricle using an 18 gauge cannula attached to virgin
TABLE 3

polypropylene syringes. TWenty to ?fty milliliters of CSF

Subject demographic data for living probable AD and control subjects.

Were WithdraWn, centrifuged at 10,000 g to pellet cells and
aliquoted into 2 ml cryovials. The vials Were immediately
froZen in liquid nitrogen and maintained at —800 C. until used
for analysis. For speci?city studies CSF specimens Were

Mean 1 SEM

Age (y)

Sex

Mean 1

obtained in a similar manner from 5 subjects With diffuse

Mean : MMSE

SEM

Score

TTR (ngml)

LeWy body disease (LB), 2 subjects With Parkinson’s disease
(PD), 2 subjects With parasupranuclear palsy (PSP) and 3
subjects With frontotemporal dementia (FTD). Subjects used

20
Control

71.0 r 1.9

ProbableAD

68.4 r 1.8

10 M/4 F

5 M/10 F

29.2 r 0.2

37.5 r 62*

19.3 114*

1.9 11.9

in these studies met standard histopathologic criteria for the

diagnosis ofAD (Mirra et al. Neurology 91 :479-484 (1991);
NIA-Reagan Institute Neurobiol Aging 18:S1-2 (1997). All
control patients Were folloWed longitudinally at the Univer

*p < 0.05
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Table 4 shoWs results of the analyses for individual subjects
and shoWs that 13 of 14 control subjects had complexed TTR
concentrations beloW the LOD Whereas all 15 probable AD
subjects had levels higher than the LOD. Mean complexed
TTR concentrations in AD lumbar CSF (37516.2 ng/ml)
Were ~1/3 those observed in ventricular CSF (110:5 ng/ml)

in the normal range. All MCI patients Were normal on enroll

ment into the University of Kentucky’s longitudinal study
30

but Were signi?cantly higher than the mean level in control

subjects (6111.6 ng/ml). The control meanzSEM Was calcu
lated using 5 ng/ml for LOD values.

sity of Kentucky AlZheimer’s Disease Center (ADC) Clinic
and had neurop sychological testing annually Which remained

35

and developed MCI during folloW up. The criteria used for
clinical diagnosis of amnesic MCI Were those described by
Petersen (Petersen et al. Arch Neurol 56:303-308 (1999) and

include: 1) memory complaints corroborated by an infor
mant, 2) objective memory impairment for age and education,
3) normal general cognitive function, 4) intact activities of
daily living, and 5) the subject does not meet criteria for
dementia. The clinical criteria for EAD Were 1) a decline in

cognitive function for a previous higher level, 2) declines in
TABLE 4

one or more areas of cognition in addition to memory, 3) a

Individual complexed TTR concentrations

for living probable AD and control subjects.
Control

<5
<5
<5
<5
<5
<5
<5
<5
<5
<5
<5
<5
<5

ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
26.5

Mean:SEM=6.1 : 1.6
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All subjects had neuropathological evalution of sections of
neocortex, hippocampus, entorhinal cortex, amygdala, basal
ganglia, nucleus basalis of Meynert, midbrain, pons, medulla,
and cerebellum using the modi?ed BielschoWsky stain,

Probable AD

40.5
32.5
50.5
46
26
69.5
53.5
24.5
22.5
21.0
26.5
109.5
25.5
19.5
6.0

45

50

stain on sections of entorhinal cortex, hippocampus, and
amygdala, and the BielschoWsky stain on the neocortex.
None of the MCI, EAD, LAD, or control subjects demon

strated signi?cant LeWy body pathology. The distinction
betWeen MCI and control patients Was a signi?cant increase

in neuritic plaques in neocortical regions and a signi?cant
55

increase in neuro?brillary tangles in entorhinal cortex, hip
pocampus, and amygdala in MCI patients (Markesbery et al.
Arch Neurol 63:38-46, 2006). Braak staging scores in control
subjects Were I to II and met the NIA-Reagan Institute loW

60

likelihood for the histopathological diagnosis of AD. The
Braak staging scores of MCI subjects ranged from III to IV.
EAD subjects met high likelihood criteria for the histo
pathogical diagnosis of AD With a Braak staging score of V.
Braak staging scores in AD subjects Were VI. Subjects With
non-AD pathologies met standard histopathologic criteria for
each disease.

a speci?city of 93%. Correlation analysis of levels of com
plexed TTR and MMSE scores shoWed a statistically signi?

cant (p<0.001) negative correlation (r:—0.68) suggesting lev
els of the complex increase as cognitive function declines.
Comparison of concentrations of complexed TTR as a func
tion of gender shoWed no gender related differences.

hemotoxylin-eosin stain, and 10D-5 and alpha synuclein
immunostains. Braak staging (Braak and Braak Acta Neuro
pathol 82:239-259 (1991) Was determined using the Gallyas

Mean: SEM=37.5 16.2

Calculation of sensitivity and speci?city values for this
relatively small sample siZe shoWed a sensitivity of 100% and

clinical dementia rating scale score of 0.5 to 1, and 4) a
clinical examination that excluded other causes of dementia.

65

Lumbar CSF samples Were collected from subjects diag
nosed With probable AlZheimer’s disease (N:15) and sub
jects diagnosed as normal (non-demented) (N:14) the mom
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Complexed transthyretin concentrations (ng/ml CSF) are

ing after fasting since midnight. The L3-4 or L4-5 interspace
Was in?ltrated With 1% lidocaine using a 25 gauge needle for

calculated based on the intensity of color developed from the

super?cial and deep anesthesia. Lumbar puncture Was per
formed With the patient in lateral decubitus or sitting using a
24 gauge Sprotte bullet tip atraumatic spinal needle and a 20
gauge spinal introducer. CSF Was WithdraWn using virgin 5
ml polypropylene syringes. Subjects Were analyZed in a
blinded fashion and Were either probableAD subjects (N:1 5)
or age-matched controls (N:14).

horseradish peroxidase labeled secondary antibody and the
TMB color reagent. The calibration curves constructed for

each plate demonstrate linearity of response betWeen color
change as measured by absorbance at 450 nm and concentra

tion of tranthyretin. The color development only occurs When

the protein complex is present. For example, if uncomplexed
prostaglandin-D-synthase is trapped during the initial phase
of the measurement, it Will not react With the subsequent

EXAMPLE 2

antibody that recogniZes only transthyretin. Antibody speci

Measuring Levels of Biomarkers

immunizing protein or peptide that blocked immunolabeling

?city Was veri?ed by preincubation of the antibodies With
in Western blots.

To measure levels of the protein complex in CSF, a sand

Throughout this application, various publications are ref
erenced. All such publications are hereby incorporated herein
by reference in their entirety.
The invention thus being described, it Would be obvious

Wich ELISA has been developed using standard protocols as
described in Techniques in Molecular Biology and as shoWn
schematically in FIG. 6. To trap the complex of interest,
96-Well plates Were coated overnight at 40 C. by adding 200 pl

1 pg/ml rat anti-human prostaglandin-D-synthase (Cayman
Chemical, Ann Arbor, Mich. Catalog # 10004342) raised
against recombinant human prostaglandin-D-synthase in
PBS containing 0.1% NaN3 (PBSN) per Well. For quanti?ca
tion, one roW of the plate is coated overnight With puri?ed
human transferin (Sigma Chemical, St. Louis, Mo.) at 25

20

that the same may be varied in many Ways. All such variances
as considered to be embodiments of the present invention and

not departures therefrom.
We claim:

1. A method for aiding diagnosis of mild cognitive impair
ment or AlZheimer’s Disease in an individual, comprising:
25

(a) obtaining a sample of cerebrospinal ?uid from the indi

ng/ml, 50 ng/ml, 125 ng/ml, 250 ng/ml, and 500 ng/ml in
PBSN. After rinsing 5 times With PBSN (200 pl/Wash), the

(b) measuring an amount of and/or a concentration of a

plates are blocked for 2 hr With 100 pl 5% dry milk/15% goat

protein biomarker complex that comprises transthyretin

serum in PBSN. The plates are Washed 5 times With PBST and
incubated 1 hr at room temperature With 50 pl untreated CSF.
The plates are Washed 5 times With PBST and are incubated 1

hr With 1 pg/ml rabbit anti-human transthyretin (Santa CruZ
Biotechnology, Santa CruZ, Calif.; Catalog # sc-13098) pre
pared in 5% drymilk/PBSN. The transthyretin antibody is
raised against amino acids 1-147 presenting full length
human transthyretin. FolloWing 5 Washes in PBSN the plates

vidual;
and prostaglandin-H2 isomerase in said sample; and
30

to a reference value, Wherein a greater measured amount

and/or concentration of the biomarker complex as com
pared to the reference value is indicative of a higher
likelihood that the individual is afflicted with mild cog
35

are incubated With a 1:1000 dilution of horseradish peroxi

40

100 pl 3,3',5,5'-tetramethylbenZidine (TMB) color reagent
(Alpha Diagnostics, San Antonio, Tex.; Catalog # 80091) is
45

450 nm using a multi-Well plate reader. Blanks for the assay

mined. MeanzSEM limits of detection of complexed tran
sthyretin are 3.6107 ng/ml. MeaniSEM correlation coeffi
cients for replicate analyses of the calibration curve are

0.92:0.02 (p<0.01).

based on a value from one or a plurality of samples obtained
from the individual at one or a plurality of earlier points in

time.
4. The method of claim 2, Wherein the reference value is

consist of all reagents except CSF. Samples are analyZed in
quadruplicate. To prevent edge effects the outer roWs and
columns of the plate are not used. Linear calibration curves
are calculated for each plate and concentrations of CSF deter

the plurality of samples comprises at least one sample from
each of a plurality of individuals afflicted with mild cognitive
impairment or AlZheimer’s disease.
3. The method of claim 1, Wherein the reference value is

added to each Well for 30 minutes for color development. The

reaction is stopped by addition of 50 pl stopping solution
(Alpha Diagnostics, Catalog # 80100). The plates are read at

nitive impairment or AlZheimer’s disease, thereby aid
ing diagnosis of mild cognitive impairment or AlZhe
imer’s disease in the individual.
2. The method of claim 1, Wherein the reference value is
based on a value from each of a plurality of samples, Wherein

dase conjugated goat anti rabbit IgG (Jackson lmmunore
search, Laboratories, West Grove, Pa.; Catalog # 1 1 1035003)
for 1 hr at room temperature. Following 5 Washes in PBST,

(c) comparing the measured amount and/ or concentration

50

less than about 5 ng/mL.
5. The method of claim 2, Wherein the reference value is
about 5 ng/mL.
6. The method of claim 2, Wherein the reference value is 5

ng/mL.

